Prevotella buccae

(aka Bacteroides buccae)

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Prevotella buccae, (aka Bacteroides buccae), is a Gram-negative, non-spore-forming, anaerobic, non-motile, rod-shaped bacterium. It has been detected in at least 14 gut microbiome compilation studies or metastudies. The DNA G+C content is 52%. Prevotella buccae is probably a common, although minor, coloniser of the gut. (Shah1990; Shah2010Bergeys; Holdeman1982; Shah1981; Watabe1983a)



  • This organism has been recovered from human faeces, dental disease, and oral flora. The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread (notes: human and animal pathogen). It is an opportunistic pathogen. Is a known gut commensal.
    • GENERAL CHARACTERISTICS (Shah1990); (Shah2010Bergeys); (Holdeman1982); (Shah1981); (Watabe1983a);
    Character Response
  • Substrates hydrolysed or digested:
  • aesculin; gelatin; milk; starch;
  • 💧
  • Bile tolerance:
  • Doesn't tolerate 20% bile
  • 🌡
  • Temperature tolerance:
  • grows at 37℃;
  • H+
  • Acid from carbohydrates usually produced:
  • arabinose; D-arabinose; fructose; glucose; mannose; rhamnose; glycogen; starch; cellubiose; lactose; melibiose; raffinose; sucrose; salicin;
  • Active enzymes:
  • Ala arylamidase; alkaline phosphatase; α-galactosidase; β-galactosidase; α-glucosidase; β-glucosidase; Glu-Glu arylamidase; Leu-Gly arylamidase; xylosidase;
    • SPECIAL FEATURES (Shah1990); (Shah2010Bergeys); (Holdeman1982); (Shah1981); (Watabe1983a);
    Character Response
  • ✓
  • Metabolites produced:
  • formate (minor); acetate; isobutyrate (minor); succinate; isovalerate (minor);
  • ✗
  • Metabolites not produced:
  • H₂; indole;
  • ✗
  • Nitrate:
  • not reduced
  • ✗
  • Pigments:
  • not produced
    • RESPONSE TO ANTIBIOTICS (Goldstein2018a); (Goldstein2013a); (Goldstein2013b); (Citron2011); (Goldstein2006); (Goldstein2006c); (Citron2003); (Goldstein2003a); (Citron2001); (Goldstein2000); (Goldstein2000a); (Goldstein1999); (Goldstein1999a); (Goldstein1999b); (Citron1997); (Holdeman1982); (Shah1981);
    Class Active Resistant
  • Penicillins:
  • amoxicillin-clavulanic acid; ampicillin-sulbactam; doripenem; ertapenem; imipenem; meropenem; penicillin; piperacillin-tazobactam;
  • ampicillin; piperacillin; ticarcillin;
  • Cephalosporins:
  • cefoxitin;
  • ceftazidime;
  • Macrolides:
  • azithromycin; clarithromycin; erythromycin; quinupristin-dalfopristin; roxithromycin; telithromycin;
  • fidaxomicin;
  • Tetracyclines:
  • minocycline; tigecycline;
  • tetracycline;
  • Quinolines:
  • ciprofloxacin; clinafloxacin; garenoxacin; gatifloxacin; gemifloxacin; levofloxacin; moxifloxacin; ofloxacin; trovafloxacin;
  • Heterocycles:
  • chloramphenicol; metronidazole;
  • Vancomycins:
  • vancomycin;
  • Miscellaneous antibiotics:
  • clindamycin; linezolid; ranbezolid; telithromycin;

  • Prevotella species at mucosal sites to localized and systemic disease, including periodontitis, bacterial vaginosis, rheumatoid arthritis, metabolic disorders and low_grade systemic inflammation. Intriguingly, Prevotella abundance is reduced within the lung microbiota of patients with asthma and chronic obstructive pulmonary disease. Increased Prevotella abundance is associated with augmented T helper type 17 (Th17) _mediated mucosal inflammation, which is in line with the marked capacity of Prevotella in driving Th17 immune responses in vitro. Studies indicate that Prevotella predominantly activate Toll_like receptor 2, leading to production of Th17_polarizing cytokines by antigen_presenting cells, including interleukin_23 (IL_23) and IL_1. Furthermore, Prevotella stimulate epithelial cells to produce IL_8, IL_6 and CCL20, which can promote mucosal Th17 immune responses and neutrophil recruitment. Prevotella_mediated mucosal inflammation leads to systemic dissemination of inflammatory mediators, bacteria and bacterial products, which in turn may affect systemic disease outcomes. [PMID: 28542929]

  • GutFeeling KnowledgeBase COMMENTS [Website]

    Prevotella species are anaerobic Gram_negative bacteria of the Bacteroidetes phylum, which also includes the clinically important genera Bacteroides and Porphyromonas. Prevotella strains are classically considered commensal bacteria due to their extensive presence in the healthy human body and their rare involvement in infections. Only a few strains have been reported to give rise to opportunistic endogenous infections, including chronic infections, abscesses and anaerobic pneumonia. [PMID: 28542929]

  • McLaughlin, S. D., Walker, A. W., Churcher, C., Clark, S. K., Tekkis, P. P., Johnson, M. W., Parkhill, J., Ciclitira, P. J., Dougan, G., Nicholls, R. J., & Petrovska, L. (2010). The bacteriology of pouchitis: a molecular phylogenetic analysis using 16S rRNA gene cloning and sequencing. Annals of Surgery, 252(1), 90–98.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Bacteroidetes Class:  Bacteroidia Order:  Bacteroidales Family:  Prevotellaceae Genus:  Prevotella Alt. name:  Bacteroides buccae Gram stain:  neg O2 Relation.:  anaerobic Spore:  No spore Motility:  Sessile Morphology:  Rod Pigment:  neg
    Health:  Unknown
    Source:  human faeces, dental disease, and oral flora
    DNA G+C(%):  52
    Mid T(℃):  37(+)
    Bile reaction(%):  20(neg)
    		Aesculin:  + Urea:  neg Gelatin:  d(+) Starch:  + Milk:  + Meat:  neg
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  + D-Arabinose:  + Fructose:  + Glucose:  + Mannose:  + Rhamnose:  + Xylose:  vr Cellubiose:  + Lactose:  + Maltose:  vr Melezitose:  neg Melibiose:  + Sucrose:  + Trehalose:  neg Glycogen:  + Starch:  + Glycerol:  neg Inositol:  neg Mannitol:  neg Sorbitol:  neg Salicin:  +
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Catalase:  neg Urease:  neg G6PDH6PGDH:  neg Ac-β-glcamnd:  neg α-Fucosidase:  neg α-Galactosidase:  + β-Galactosidase:  + α-Glucosidase:  + β-Glucosidase:  + β-Glucuronidase:  neg Xylosidase:  + ArgDH:  neg GluDC:  neg GlyAP:  neg AlanineAA:  + GluGluAA:  + GlyAA:  neg LeuAA:  neg LeuGlyAA:  + PyrrolidAA:  neg AlkalineP:  +
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Formate:  minor(+) Acetate:  + Isobutyrate:  minor(+) Succinate:  + Isovalerate:  minor(+) H2:  neg Indole:  neg Pigment:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    amoxicillin:  Var(MIC50): ≤0.125, MIC90: 32, RNG: (≤0.0125-64)
    Augmentin:  S(MIC50): 0.125, MIC90: 1, RNG: (≤0.015-1)
    ampicillin:  R(MIC50): 64, MIC90: >128, RNG: (0.03->128)
    amp-sulb:  S(MIC50): 0.5, MIC90: 1, RNG: (0.125-4)
    penicillin:  S(MIC50): 0.06, MIC90: 8, RNG: (0.06–32)
    penicillin_G:  Var(MIC50): 0.125, MIC90: >32, RNG: (≤0.03->32)
    piperacillin:  R(MIC50): 64, MIC90: 64, RNG: (0.25-128)
    piper-taz:  S(MIC50): ≤0.125, MIC90: ≤0.125, RNG: (≤0.125-2)
    ticarcillin:  R(MIC50): 16, MIC90: 32, RNG: (0.06-64)
    tica-clav:  Var(MIC50): 0.5, MIC90: 32, RNG: (0.06->128)
    doripenem:  S(MIC50): 0.06, MIC90: 0.125, RNG: (0.06-0.125)
    ertapenem:  S(MIC50): 0.125, MIC90: 0.125, RNG: (0.06-0.125)
    imipenem:  S(MIC50): 0.062, MIC90: 0.25, RNG: (0.03-0.5)
    meropenem:  S(MIC50): 0.062, MIC90: 0.12, RNG: (0.06-0.12)
    cefalexin:  Var(MIC50): 2, MIC90: >32, RNG: (0.06->32)
    cefamandole:  Var(MIC50): 4, MIC90: 128, RNG: (0.125-128)
    cefmetazole:  Var(MIC50): 2, MIC90: 64, RNG: (0.12->128)
    cefoperazone:  Var(MIC50): 2, MIC90: 16, RNG: (0.125-16)
    cefotaxime:  Var(MIC50): 2, MIC90: >32, RNG: (0.06->32)
    cefotetan:  Var(MIC50): 1, MIC90: 64, RNG: (0.125-64)
    cefotiam:  Var(MIC50): 1, MIC90: >128, RNG: (0.125->128)
    cefoxitin:  S(MIC50): 1, MIC90: 16, RNG: (0.06–16)
    ceftazidime:  R(MIC50): 32, MIC90: 128, RNG: (2–>128)
    ceftizoxime:  Var(MIC50): 0.5, MIC90: 16, RNG: (0.125-16)
    cefuroxime:  Var(MIC50): 4, MIC90: >32, RNG: (0.125–>32)
    azithromycin:  S(MIC50): 0.125, MIC90: 1, RNG: (0.06->32)
    erythromycin:  S(MIC50): 0.125, MIC90: 0.5, RNG: (≤0.03->32)
    fidaxomicin:  R(MIC50): >512, MIC90: >512, RNG: (64->512)
    clarithromycin:  S(MIC50): 0.125, MIC90: 0.25, RNG: (0.06-1)
    quin-dalf:  S(MIC50): 1, MIC90: 2, RNG: (≤0.0125-4)
    roxithromycin:  S(MIC50): 1, MIC90: 4, RNG: (0.06–8)
    telithromycin:  S(MIC50): 0.25, MIC90: 1, RNG: (0.125-8)
    linezolid:  S(MIC50): 1, MIC90: 2, RNG: (0.25-2)
    ciprofloxacin:  S(MIC50): 1, MIC90: 4, RNG: (≤0.5->8)
    clinafloxacin:  S(0.06/2)
    garenoxacin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.016-0.5)
    gatifloxacin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.06-2)
    gemifloxacin:  S(MIC50): 1, MIC90: 2, RNG: (0.03-8)
    levofloxacin:  S(MIC50): 0.5, MIC90: 2, RNG: (≤0.06->8)
    moxifloxacin:  S(MIC50): 0.5, MIC90: 0.5, RNG: (0.03-2)
    ofloxacin:  S(MIC50): 0.5, MIC90: 2, RNG: (0.06-4)
    sparfloxacin:  Var(MIC50): 2, MIC90: 8, RNG: (1–8)
    trovafloxacin:  S(MIC50): 1, MIC90: 2, RNG: (0.25-4)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    doxycycline:  Var(MIC50): 0.25, MIC90: 8, RNG: (0.032-16)
    minocycline:  S(MIC50): 0.06, MIC90: 8, RNG: (0.03–8)
    tetracycline:  R(MIC50): 8, MIC90: 32, RNG: (0.125->32)
    tigecycline:  S(MIC50): 0.125, MIC90: 0.5, RNG: (0.06–4)
    teicoplanin:  Var(MIC50): 2, MIC90: 16, RNG: (≤0.06->16)
    vancomycin:  R(MIC50): >16, MIC90: >16, RNG: (1->16)
    bacitracin:  Var(MIC50): 2, MIC90: 32, RNG: (0.5–32)
    chloramphenicol:  S(MIC50): 2, MIC90: 4, RNG: (1-4)
    metronidazole:  S(MIC50): 0.5, MIC90: 1, RNG: (0.06-2)
    ranbezolid:  S(MIC50): 0.03, MIC90: 0.125, RNG: (≤0.008-0.25)
    clindamycin:  S(MIC50): ≤0.03, MIC90: ≤0.03, RNG: (≤0.03->32)

    References

    SPECIFIC REFERENCES FOR PREVOTELLA BUCCAE
  • Shah1990 - Notes: Prevotella, a New Genus To Include Bacteroides melaninogenicus and Related Species Formerly Classified in the Genus Bacteroides.
  • Shah2010Bergeys - Bergey's manual of systematic bacteriology. Vol. 4, The Bacteroidetes. Family Prevotellaceae, Genus I. Prevotella
  • Maji2018 - Gut microbiome contributes to impairment of immunity in pulmonary tuberculosis patients by alteration of butyrate and propionate producers
  • Goldstein2018a - Comparative In Vitro Activities of Relebactam, Imipenem, the Combination of the Two, and Six Comparator Antimicrobial Agents against 432 Strains of Anaerobic Organisms, Including Imipenem-Resistant Strains.
  • Goldstein2013a - Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates.
  • Goldstein2013b - Comparative in vitro activities of GSK2251052, a novel boron-containing leucyl-tRNA synthetase inhibitor, against 916 anaerobic organisms.
  • Citron2011 - In vitro activity of ceftazidime-NXL104 against 396 strains of beta-lactamase-producing anaerobes.
  • Goldstein2006 - In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.
  • Goldstein2006c - Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents.
  • Citron2003 - In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
  • Goldstein2003a - In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
  • Citron2001 - Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.
  • Goldstein2000 - Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens.
  • Goldstein2000a - Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections.
  • Goldstein1999 - In vitro activity of gemifloxacin (SB 265805) against anaerobes.
  • Goldstein1999a - Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections.
  • Goldstein1999b - Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes.
  • Citron1997 - Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections.
  • Holdeman1982 - Bacteroides oris and Bacteroides buccae New Species from Human Periodontitis and Other Human Infections.
  • Shah1981 - Bacteroides buccalis, sp. nov., Bacteroides denticola, sp. nov., and Bacteroides pentosaceus, sp. nov., new species of the genus Bacteroides from the oral cavity.
  • Watabe1983a - Taxonomic Study of Bacteroides oralis and Related Organisms and Proposal of Bacteroides veroralis sp. nov.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR PREVOTELLA BUCCAE
  • Almeida2019 - A new genomic blueprint of the human gut microbiota.
  • Benno1986 - Comparison of the fecal microflora in rural Japanese and urban Canadians.
  • Benno1989 - Comparison of fecal microflora of elderly persons in rural and urban areas of Japan.
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • Chung2019 - Impact of carbohydrate substrate complexity on the diversity of the human colonic microbiota.
  • Dubinkina2017 - Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • McLaughlin2010 - The bacteriology of pouchitis: a molecular phylogenetic analysis using 16S rRNA gene cloning and sequencing.
  • Minerbi2019 - Altered microbiome composition in individuals with fibromyalgia
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Walker2011 - High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease.
  • Wang2020a - Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents
  • Zeller2014 - Potential of fecal microbiota for early-stage detection of colorectal cancer
  • ...............................
    • GENERAL REFERENCES FOR PREVOTELLA BUCCAE
  • CCUG - Culture Collection University of Gothenburg - Entire Collection
    • Added: April 08, 2021